Figure 1.

Cancer-associated inflammation promotes upregulation of JAM-A on peripheral monocytes in an IL-1β-dependent manner. (A) Frequency of JAM-A⁺ cells within the most abundant immune cell populations in the blood of mice with sc. LLC tumors (21 days post-engraftment, 1678 ± 212mm³ tumor volume). (B) Same as (A) in orthothopic Py8119 breast tumors (32 days post-engraftment, 1199 ± 114mm³ tumor volume). (C) Frequency of JAM-A⁺ cells within the most abundant immune cell populations in the blood of MMTV-PyMT mice at early stage (no palpable tumor) and late stage (tumor volume reached 1500 mm³) of tumor progression. Dots connected with line denote values from the same animal. (D) Representative flow cytometry dot plots of JAM-A expression in Ly6C^hi monocytes from the blood. (E) Changes in the frequency of JAM-A⁺ cells within Ly6C^hi monocytes during tumor progression in the blood of mice with orthotopic Py8119 tumors or sc. LLC tumors (corresponding tumor volumes are shown in Supplementary Figure 2 ). (F) Frequency of JAM-A⁺ cells within Ly6C^hi monocytes in the spleen and bone marrow (BM) of mice with orthotopic Py8119 tumors or sc. LLC tumors (time post-engraftment and tumor volume as in panels A and B). (G) JAM-A expression on GFP⁺ Ly6C^hi bone marrow-derived monocytes adoptively transferred into LLC tumor-bearing mice on day 18 of tumor development. (H) Fold change of JAM-A⁺ cells within Ly6C^hi monocytes in the blood of Il1b ^+/+ or Il1b ^-/- mice with sc. LLC tumors (day 19 post-engraftment) or orthotopic Py8119 tumors (day 35 post-engraftment) compared to naive Il1b ^+/+ mice (tumor burden is shown in Supplementary Figure 3 ). Cell type frequencies were determined using flow cytometry. Graphs show mean and SEM. Panel (C) paired two-tailed t-test; All other panels: unpaired two-tailed t-test; *P < 0.05, **P < 0.01, ***P < 0.001.